RecruitingNCT06480591

Evaluation of the Pathobiology of CALR-mutated MPN Cells

Sponsor

Wake Forest University Health Sciences

Enrollment

35 participants

Start Date

Jan 21, 2025

Study Type

OBSERVATIONAL

Conditions

Myeloproliferative Neoplasm

Summary

The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Blood Draw for people with myeloproliferative neoplasm. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.